Axsome Therapeutics, Inc.
AXSM
Rank in Stocks
#2338
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Share Price
$160.25
Market Cap
$8.39B
Change (1 day)
2.85%
Change (1 year)
21.77%
Country
US
Trade Axsome Therapeutics, Inc. (AXSM)
Category
Healthcare
Number of shares outstanding for Axsome Therapeutics, Inc. (AXSM)
Number of shares outstanding as of June 2026: 51.50M
According to Axsome Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 51.50M. At the end of December 2023 the company had 45.43M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Axsome Therapeutics, Inc. (AXSM) from 2013 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 51.50M | 7.49% |
| 2024 | 47.91M | 5.48% |
| 2023 | 45.43M | 11.73% |
| 2022 | 40.66M | 8.07% |
| 2021 | 37.62M | 1.11% |
| 2020 | 37.21M | 9.37% |
| 2019 | 34.02M | 26.55% |
| 2018 | 26.88M | 18.09% |
| 2017 | 22.76M | 18.87% |
| 2016 | 19.15M | 60.32% |
| 2015 | 11.95M | -6.08% |
| 2014 | 12.72M | 62.59% |
| 2013 | 7.82M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 393.00% |
US
|
|
| 396.00M | 668.92% |
US
|
|
| 478.91M | 829.91% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 20.75% |
NL
|
